The clinical course and role of surgery in pediatric malignant peripheral nerve sheath tumors: a database study

Victor M. Lu MD, PhD1, Shelly Wang MD, MPH1,2, David J. Daniels MD, PhD3, Robert J. Spinner MD3, Allan D. Levi MD, PhD1, and Toba N. Niazi MD1,2
View More View Less
  • 1 Department of Neurological Surgery, University of Miami;
  • | 2 Department of Neurological Surgery, Nicklaus Children’s Hospital, Miami, Florida; and
  • | 3 Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

OBJECTIVE

Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors found throughout the body, with their clinical course in children still not completely understood. Correspondingly, this study aimed to determine survival outcomes and specific clinical predictors of survival in this population from a large national database.

METHODS

All patients with MPNSTs aged ≤ 18 years in the US National Cancer Database (NCDB) between 2005 and 2016 were retrospectively reviewed. Data were summarized, and overall survival was modeled using Kaplan-Meier and Cox regression analyses.

RESULTS

A total of 251 pediatric patients with MPNSTs (132 [53%] females and 119 [47%] males) were identified; the mean age at diagnosis was 13.1 years (range 1–18 years). There were 84 (33%) MPNSTs located in the extremities, 127 (51%) were smaller than 1 cm, and 22 (9%) had metastasis at the time of diagnosis. In terms of treatment, surgery was pursued in 187 patients (74%), chemotherapy in 116 patients (46%), and radiation therapy in 129 patients (61%). The 5-year overall survival rate was estimated at 52% (95% CI 45%–59%), with a median survival of 64 months (range 36–136 months). Multivariate regression revealed that older age (HR 1.10, p < 0.01), metastases at the time of diagnosis (HR 2.14, p = 0.01), and undergoing biopsy only (HR 2.98, p < 0.01) significantly and independently predicted a shorter overall survival. Chemotherapy and radiation therapy were not statistically significant.

CONCLUSIONS

In this study, the authors found that older patient age, tumor metastases at the time of diagnosis, and undergoing only biopsy significantly and independently predicted poorer outcomes. Only approximately half of patients survived to 5 years. These results have shown a clear survival benefit in pursuing maximal safe resection in pediatric patients with MPNSTs. As such, judicious workup with meticulous resection by an expert team should be considered the standard of care for these tumors in children.

ABBREVIATIONS

MPNST = malignant peripheral nerve sheath tumor; NCDB = National Cancer Database; NF1 = neurofibromatosis type 1.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res. 2013;33(6):25972604.

    • Search Google Scholar
    • Export Citation
  • 2

    Martin E, Flucke UE, Coert JH, van Noesel MM. Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease. Childs Nerv Syst. 2020;36(10):24532462.

    • Search Google Scholar
    • Export Citation
  • 3

    Ferrari A, Miceli R, Rey A, Oberlin O, Orbach D, Brennan B, et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer. 2011;47(5):724731.

    • Search Google Scholar
    • Export Citation
  • 4

    Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):20062021.

    • Search Google Scholar
    • Export Citation
  • 5

    Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology. 2003;61(5):696698.

    • Search Google Scholar
    • Export Citation
  • 6

    Wilson MP, Katlariwala P, Low G, Murad MH, McInnes MDF, Jacques L, Jack AS. Diagnostic accuracy of MRI for the detection of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis. AJR Am J Roentgenol. 2021;217(1):3139.

    • Search Google Scholar
    • Export Citation
  • 7

    Bhattacharyya AK, Perrin R, Guha A. Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol. 2004;69(1-3):335349.

    • Search Google Scholar
    • Export Citation
  • 8

    Perrin RG, Guha A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2004;15(2):203216.

  • 9

    Gupta G, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Focus. 2007;22(6):E12.

  • 10

    Powers CJ, Friedman AH. A brief history of surgery for peripheral nerve sheath tumors. Neurosurg Focus. 2007;22(6):E1.

  • 11

    Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:7784.

    • Search Google Scholar
    • Export Citation
  • 12

    Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol. 2013;20(6):17591765.

    • Search Google Scholar
    • Export Citation
  • 13

    Lu VM, Di L, Eichberg DG, Luther EM, Shah AH, Daniels DJ, et al. Age of diagnosis clinically differentiates atypical teratoid/rhabdoid tumors diagnosed below age of 3 years: a database study. Childs Nerv Syst. 2021;37(4):10771085.

    • Search Google Scholar
    • Export Citation
  • 14

    Lu VM, Shah AH, Eichberg DG, Quinones-Hinojosa A, Esquenazi Y, Komotar RJ, Ivan Me. Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: insights from a national database. J Neurooncol. 2020;147(3):711720.

    • Search Google Scholar
    • Export Citation
  • 15

    Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23(33):84228430.

    • Search Google Scholar
    • Export Citation
  • 16

    van Noesel MM, Orbach D, Brennan B, Kelsey A, Zanetti I, de Salvo GL, et al. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: an analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer. 2019;66(10):e27833.

    • Search Google Scholar
    • Export Citation
  • 17

    Amirian ES, Goodman JC, New P, Scheurer ME. Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. J Neurooncol. 2014;116(3):609616.

    • Search Google Scholar
    • Export Citation
  • 18

    Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg. 2013;118(1):142148.

    • Search Google Scholar
    • Export Citation
  • 19

    Montano N, D’Alessandris QG, D’Ercole M, Lauretti L, Pallini R, Di Bonaventura R, et al. Tumors of the peripheral nervous system: analysis of prognostic factors in a series with long-term follow-up and review of the literature. J Neurosurg. 2016;125(2):363371.

    • Search Google Scholar
    • Export Citation
  • 20

    Kahn J, Gillespie A, Tsokos M, Ondos J, Dombi E, Camphausen K, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014;4:324.

    • Search Google Scholar
    • Export Citation
  • 21

    Safaee MM, Lyon R, Barbaro NM, Chou D, Mummaneni PV, Weinstein PR, et al. Neurological outcomes and surgical complications in 221 spinal nerve sheath tumors. J Neurosurg Spine. 2017;26(1):103111.

    • Search Google Scholar
    • Export Citation
  • 22

    Ziadi A, Saliba I. Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review. Auris Nasus Larynx. 2010;37(5):539545.

    • Search Google Scholar
    • Export Citation
  • 23

    Miao R, Wang H, Jacobson A, Lietz AP, Choy E, Raskin KA, et al. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol. 2019;137:6170.

    • Search Google Scholar
    • Export Citation
  • 24

    Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018;36(2):8594.

  • 25

    Askins MA, Moore BD III. Preventing neurocognitive late effects in childhood cancer survivors. J Child Neurol. 2008;23(10):11601171.

  • 26

    Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG),. Spanish (GEIS), French (FSG), and Polish (PSG). Sarcoma Groups. J Clin Oncol. 2020;38(19):21782186.

    • Search Google Scholar
    • Export Citation
  • 27

    Sobczuk P, Teterycz P, Czarnecka AM, Świtaj T, Koseła-Paterczyk H, Kozak K, et al. Systemic treatment for advanced and metastatic malignant peripheral nerve sheath tumors—a sarcoma reference center experience. J Clin Med. 2020;9(10):E3157.

    • Search Google Scholar
    • Export Citation
  • 28

    Mowery A, Clayburgh D. Malignant peripheral nerve sheath tumors: analysis of the national cancer database. Oral Oncol. 2019;98:1319.

  • 29

    Fang Y, Elahi A, Denley RC, Rao PH, Brennan MF, Jhanwar SC. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. Anticancer Res. 2009;29(4):12551262.

    • Search Google Scholar
    • Export Citation
  • 30

    Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, et al. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open. 2021;4(3):e210945.

    • Search Google Scholar
    • Export Citation
  • 31

    Amirnasr A, Verdijk RM, van Kuijk PF, Kartal P, Vriends ALM, French PJ, et al. Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Sci Rep. 2020;10(1):2927.

    • Search Google Scholar
    • Export Citation
  • 32

    Yolcu Y, Wahood W, Kerezoudis P, Alvi MA, Habermann EB, Bydon M. Primary central nervous system tumors: comparing two national cancer registries. World Neurosurg. 2019;128:e719e731.

    • Search Google Scholar
    • Export Citation
  • 33

    Høland M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, et al. Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Mod Pathol. 2018;31(11):16941707.

    • Search Google Scholar
    • Export Citation
  • 34

    Krawczyk MA, Karpinsky G, Izycka-Swieszewska E, Gabrych A, Kunc M, Fatyga A, et al. Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. Cancer Biomark. 2019;24(3):351361.

    • Search Google Scholar
    • Export Citation
  • 35

    Perry A. Preview of the WHO 2021 CNS Tumor Classification Scheme. Presented at: 1st Annual Brain Tumor Update Symposium; March 5, 2021;. San Francisco, CA.Accessed August 16, 2021. https://www.youtube.com/watch?v=CEY9OqSrLUA&t=436s&ab_channel=UCSF NeurosurgeryUCSFNeurosurgery

    • Search Google Scholar
    • Export Citation
  • 36

    Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, Wasif N. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878885.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 135 135 135
Full Text Views 18 18 18
PDF Downloads 22 22 22
EPUB Downloads 0 0 0